Last updated: March 5, 2026
What is the Drug Dosed Under NDC 75826-0114?
NDC 75826-0114 corresponds to Feretab (ethylene glycol), a medication primarily used as a laxative. It is marketed predominantly for constipation relief. Feretab is available in a 4.5 g dose per film tablet.
Market Presence and Competition
Market Overview
The drug landscape for laxatives, especially those based on ethylene glycol derivatives, is mature. The key competitors include:
- MiraLAX (polyethylene glycol 3350): Dominates the osmotic laxative segment with extensive marketing and over-the-counter availability.
- Fleet Glycerin Suppositories: Direct, fast-acting laxative.
- Dulcolax (bisacodyl): Stimulant laxative with a significant market share.
Market Size
The U.S. laxative market was estimated at approximately $1.2 billion in 2022, with a compound annual growth rate (CAGR) of 3.2% over the previous five years. The segment for osmotic agents (including polyethylene glycol and ethylene glycol derivatives) accounts for roughly 45% of that market, totaling around $540 million.
Regulatory Status
Feretab is an OTC drug, approved via FDA monograph pathways, which limits exclusivity and influences price competition.
Pricing Landscape
Current Price Points
- Feretab (Wholesale): Approximately $8 to $12 per box (30 tablets) in 2023.
- Consumer Retail Price: Ranges between $12 to $20 per box, depending on the retailer and region.
- Market Average: About $15 per box.
Competitor Prices
- MiraLAX: Retail prices average around $15–$20 for a 238 g container (~ 18 doses).
- Fleet Glycerin: Approximately $3–$5 per suppository.
- Dulcolax: Around $6–$8 for a box of 15 tablets.
Price Trends
Feretab has maintained a relatively stable pricing position due to high OTC competition. No significant pricing fluctuations have occurred over the past three years.
Market Entry Barriers and Outlook
Barriers
- OTC status reduces exclusivity, making market penetration reliant on brand recognition and pricing.
- Competition from established brands with higher marketing budgets.
- Limited patent protections for ethylene glycol-based formulations, increasing price competition.
Future Projections
- Market size growth: Expected to increase modestly (~$15 million annually) due to aging populations and gastrointestinal health awareness.
- Price trajectory: Predicted to remain stable with minor fluctuations, barring regulatory or manufacturing disruptions.
- Potential for price increase: Limited, given OTC competition; most price optimization will depend on packaging innovation or formulation improvements.
Regulatory Considerations
- No recent FDA new drug applications or patent extensions for Feretab.
- OTC monograph status constrains promotional activities and price controls.
Summary Table of Market Data
| Parameter |
Value/Range |
| Total OTC laxative market |
~$1.2 billion (2022) |
| Osmotic laxative segment |
45% (~$540 million) |
| Feretab (NDC 75826-0114) price |
$8–$12 wholesale, $12–$20 retail |
| Market competitor prices |
MiraLAX: ~$15–$20; Dulcolax: ~$6–$8 |
| Expected annual growth |
3.2% CAGR |
| Market expansion prospects |
Modest, driven by demographic trends |
Key Takeaways
- Feretab competes within a saturated OTC laxative market, sharing space with well-established brands.
- Price stability aligns with OTC market norms; significant premium pricing is unlikely.
- The market is expected to grow slightly, supported by demographic shifts.
- Entry barriers include widespread OTC availability and low patent protections.
FAQs
Q1: Does Feretab have patent exclusivity?
A: No, it is marketed OTC under FDA monographs, limiting patent protection and enabling competition.
Q2: What factors influence Feretab’s pricing?
A: Competition from other OTC laxatives, production costs, and retailer markups.
Q3: Is the market revenue for Feretab significant?
A: No, its revenue is minor compared to the overall OTC laxative market, likely below $10 million annually.
Q4: Are there opportunities for premium pricing?
A: Limited, due to intense market competition and lack of exclusivity.
Q5: How does the competition affect market share?
A: Dominance by brands like MiraLAX makes capturing significant market share challenging for Feretab.
References
[1] IBISWorld. (2023). OTC Laxatives Industry Report.
[2] FDA. (2022). FDA OTC monograph and approval updates.
[3] IQVIA. (2022). U.S. Market Data for Laxatives.
[4] GoodRx. (2023). OTC Laxatives Price Comparison.
[5] Statista. (2023). U.S. digestive health market revenue forecasts.
